18.54Open18.54Pre Close0 Volume1 Open Interest40.00Strike Price0.00Turnover311.42%IV8.72%PremiumDec 20, 2024Expiry Date16.49Intrinsic Value100Multiplier6DDays to Expiry2.05Extrinsic Value100Contract SizeAmericanOptions Type-0.8680Delta0.0227Gamma1.38Leverage Ratio-0.1562Theta-0.0052Rho-1.20Eff Leverage0.0065Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet